Point-of-care cancer screening could transform from an expensive, lab-dependent process into an accessible diagnostic tool available in any clinic. The breakthrough lies in repurposing CRISPR gene-editing technology as an ultrasensitive molecular detector capable of identifying cancer biomarkers in blood samples with unprecedented precision. Traditional liquid biopsy methods like next-generation sequencing require specialized laboratories and substantial financial investment, limiting their widespread adoption despite their non-invasive advantages over tissue biopsy. The CRISPR-Cas12a and Cas13a systems offer a fundamentally different approach through their programmable sequence recognition and signal amplification capabilities. Cas12a excels at detecting DNA-based cancer markers including genetic mutations and methylation patterns that indicate tumor presence, while Cas13a targets RNA molecules such as microRNAs and viral sequences associated with cancer development. These molecular scissors demonstrate remarkable sensitivity through their trans-cleavage activity, where binding to a target sequence triggers widespread cutting of nearby reporter molecules, creating an amplified signal detectable even at extremely low biomarker concentrations. The technology's compatibility with simple diagnostic formats could enable cancer screening in resource-limited settings where traditional molecular diagnostics remain inaccessible. However, several challenges persist before clinical implementation. The complexity of cancer heterogeneity means multiple biomarkers may need simultaneous detection, requiring multiplexed assay development. Standardization across different laboratories and validation in diverse patient populations will be essential for regulatory approval. Additionally, the clinical significance of detecting ultra-low levels of circulating tumor material remains under investigation, as distinguishing meaningful cancer signals from background noise requires extensive clinical correlation studies.